China Medical GatewayLoading your healthcare gateway…

Li Zhi Gang

Li Zhi Gang — Chief Physician — Thoracic Surgery — Shanghai Chest Hospital

Specialties

Surgical treatment of various thoracic diseases, including surgery for lung cancer, esophageal cancer, mediastinum, chest wall, trachea, and other thoracic procedures. Particularly skilled in: - Minimally invasive surgical treatment of lung cancer, and various complex open lung surgeries - Robotic minimally invasive esophageal surgery; conventional thoracoscopic treatment of esophageal cancer - Colonic and jejunal replacement for complex esophageal diseases, including chemical burns of the esophagus and repeated esophageal cancer surgery after gastrointestinal operations - Endoscopic resection of early esophageal tumors - Surgical treatment of high-level and cervical esophageal cancer - Salvage surgery for recurrent esophageal cancer after radical radiotherapy - Minimally invasive treatment of benign esophageal diseases, including giant hiatal hernia, gastroesophageal reflux, and achalasia - Tracheal surgery: particularly skilled in surgical treatment of high-level tracheal stenosis (including laryngotracheal stenosis), post-intubation tracheal stenosis, and various tracheoesophageal fistulas - Surgical treatment of large and recurrent chest wall tumors

Education

Doctor of Medicine

Professional Experience

Li Zhigang, male, chief physician, doctoral supervisor. Thoracic Surgery, Shanghai Chest Hospital, American Association for Thoracic Surgery Evarts A. Graham Fellow (2011-2012), Shanghai "Oriental Talent" Leading Talent, Shanghai Craftsman. In 2011, he received the most important talent training program in the international thoracic surgery community – the annual Graham Fellow training opportunity of the American Association for Thoracic Surgery, where he received systematic scientific research and clinical training at the five most important thoracic surgical centers in North America. In 2014, he was appointed Deputy Director of the Thoracic Surgery Department at Shanghai Chest Hospital, and in 2015 he concurrently served as Director of the Esophageal Surgery Department, successfully leading the team to build the largest center for complex esophageal diseases in China, establishing a "one-stop" clinical diagnostic and treatment platform for esophageal diseases—including robot-assisted minimally invasive surgery, a comprehensive treatment system for esophageal cancer including radiotherapy/chemotherapy and immunotherapy, and innovative techniques for benign gastroesophageal reflux disease using magnetic rings. He has published 63 SCI papers in high-level academic journals, including Cancer Cell (2023), J Immunother Cancer (2022), Nat Commun (2021), Ann Surg (2021), and JTCVS (2023). He has led multiple important clinical trials and presided over one key R&D project of the Ministry of Science and Technology, one international key project funded by the National Natural Science Foundation, three general projects of the National Natural Science Foundation, as well as multiple municipal/university-level projects. He was elected as an outstanding academic leader of Shanghai and a leading talent of Shanghai. . 2023 Shanghai Craftsman · 2023 Shanghai Medical Craftsman · 2022 Shanghai Chest Hospital “President's Award” · 2022 Shanghai Leading Talent · 2022 Shanghai Outstanding Academic Leader · 2022 Shanghai Jiao Tong University School of Medicine Affiliated Hospital “Outstanding Teaching Mentor Award” · 2021 Shanghai Chest Hospital “President's Award” Nomination · 2015 Shanghai Science and Technology Progress Award Third Prize (Standardized Surgical Treatment Model and Application for Esophageal Cancer, Ranked 3/5) · 2011 AATS Graham Fellowship of the American Association for Thoracic Surgery (one globally per year) 1) National Natural Science Foundation Key International (Regional) Cooperation Research Project, 82320108016, Discovery and Functional Analysis of Mechanisms Improving Immunotherapy Resistance in Targeted Chemotherapy-Resistant Neoadjuvant Therapy for Esophageal Cancer, 2024-01 to 2028-12, 2.1 million RMB, ongoing, Principal Investigator 2) National Key R&D Program, 2021YFC2501005, Research on the Dynamic Evolution Mechanism of Esophageal Carcinogenesis and the Construction of Individualized Precision Diagnosis and Treatment System, 2021-12 to 2024-12, 4.5 million RMB, ongoing, Principal Investigator 3) National Natural Science Foundation General Program, 82172756, Mechanistic Study of Oncolytic Adenovirus Expressing Dual Factors CCL5/IL-15 to Synergistically Enhance Comprehensive Immunotherapy for Esophageal Cancer, 2022-01 to 2025-12, 550,000 RMB, ongoing, Principal Investigator 4) Shanghai Oriental Talent Program Leading Project, Key Technology Innovation and System Construction for Precision Diagnosis and Treatment in Esophageal Surgery, 2024-01 to 2028-12, 800,000 RMB, ongoing, Principal Investigator 5) Shanghai Outstanding Academic Leader, 22XD1402900, Innovation and Application Promotion of Stratified Treatment and Prognostic Evaluation System for Esophageal Cancer, 2022-09 to 2025-08, 400,000 RMB, ongoing, Principal Investigator 6) Shanghai Shenkang Hospital Development Center, Second Round Key Support Project of the “Three-Year Action Plan to Promote Clinical Skills and Clinical Innovation of Municipal Hospitals”, SHDC2020CR6002, Shanghai Esophageal Cancer Specialty Cohort Database, 2020-12 to 2022-09, 3.87 million RMB, completed, Principal Investigator 7) Shanghai Jiao Tong University Affiliated Chest Hospital, Key Cultivation Project for Multidisciplinary Collaborative Innovation, YJXT20190202, Esophageal Squamous Cell Carcinoma Neoadjuvant Chemoradiotherapy Clinical Modular Assessment Diagnostic Trial (Pre-SINO Trial), 2019-01 to 2021-12, 1 million yuan, completed, Principal Investigator. 8) Shanghai Jiao Tong University School of Medicine, Double Hundred Project, Exploration of Non-Surgical Treatment Models Preserving the Esophagus for Submucosal (T1b) Esophageal Squamous Cell Carcinoma, 2018-10 to 2024-10, 2 million yuan, ongoing, Principal Investigator. 9) Shanghai Shenkang Hospital Development Center Clinical Diagnosis and Treatment Technology Demonstration Standardized Management Research Project, Integrated Diagnosis and Treatment Pathway SOP for Esophageal Cancer, SMIDF81B, 2022-11 to 2023-03, 50,000 yuan, ongoing, Principal Investigator. 10) Shanghai Jiao Tong University, Translation Medicine Collaborative Innovation Center Cooperative Research Project, TM201823, Indocyanine Green Fluorescence Tracing of Sentinel Lymph Nodes in Esophageal Cancer, 2018-08 to 2020-07, 80,000 yuan, completed, Principal Investigator. 11) Shanghai Shenkang Hospital Development Center, First Round of "Three-Year Action Plan to Promote Clinical Skills and Clinical Innovation in Municipal Hospitals," 16CR1035B, Prospective, Multicenter, Open, Randomized Controlled Study of Robot-Assisted versus Conventional Thoracic and Abdominal Laparoscopic Minimally Invasive Treatment of Esophageal Squamous Cell Carcinoma, 2017-01 to 2019-12, 1.5 million yuan, completed, Principal Investigator. 12) National Natural Science Foundation General Program, 81372472, Molecular Mechanism and Intervention Strategy of OCT4 Regulating Survivin to Promote Esophageal Cancer Proliferation, 2014-01 to 2017-12, 750,000 yuan, completed, Principal Investigator. 13) Shanghai Municipal Science and Technology Commission, Scientific Research Program, 134119a7200, Minimally Invasive Treatment of Superficial Esophageal Cancer by Endoscopic and Surgical Approaches and Its Prognostic Influencing Factors, 2013-09 to 2016-09, 100,000 yuan, completed, Principal Investigator. 14) National Natural Science Foundation General Program, 30973469, Development and Experimental Research of Highly Specific Immune Cell Therapy Vaccines for Esophageal Cancer, 2010-01 to 2012-12, 310,000 yuan, completed, Principal Investigator.

Professional Roles

Vice President of the Thoracic Surgery Branch of Shanghai Medical Association, Head of the Esophagus Study Group · Deputy Head of the Esophagus Study Group of the Thoracic Surgery Branch of China Medical Doctor Association · Standing Member of the Intelligent Equipment Technology Branch of China Medical Equipment Association · Member of the Esophageal Cancer Committee of the Chinese Anti-Cancer Association (CACA) · Member of the Endoscopist Branch of China Medical Doctor Association · Member of the Esophagus Study Group of the Thoracic and Cardiovascular Surgery Branch of Chinese Medical Association · Member of the Esophageal Cancer Committee of the Chinese Society of Clinical Oncology (CSCO) · Deputy Director of the Multidisciplinary Branch for Gastroesophageal Reflux of China Medical Promotion Association · Head of the Esophagus Study Group of Chinese Digestive Surgery Elite Forum · Member of the American Association for Thoracic Surgery (AATS) · Member of the International Society for Diseases of the Esophagus (ISDE)

Return to Home